(Total Views: 556)
Posted On: 06/15/2025 9:30:19 PM
Post# of 154624
Pembrolizumab (KEYTRUDA) is the only checkpoint inhibitor currently approved by the FDA for pediatric patients with certain solid tumors. Specifically, it's approved for unresectable or metastatic TMB-H (tumor mutational burden-high) solid tumors that have progressed after prior treatment and lack satisfactory alternative options. This approval includes both adult and pediatric patients.
___
& from the internet:
The patent for Keytruda (pembrolizumab) is set to expire in the United States on December 12, 2028. In the European Union, the patent is expected to expire on June 13, 2031.
Merck is working on developing new formulations and technologies to maintain its market share after the patent expires.
___
Cytodyn Feb. 24, 2025:
Based on these survival observations, the Company has initiated two pre-clinical studies in mTNBC that will evaluate possible treatment synergies between leronlimab, an antibody-drug complex treatment (sacituzumab govitecan), and an immune checkpoint inhibitor (pembrolizumab).
___
So Merck is the obvious LL/ICI combo for pediatric solid tumors. Which solids are 40% of
___
& from the internet:
The patent for Keytruda (pembrolizumab) is set to expire in the United States on December 12, 2028. In the European Union, the patent is expected to expire on June 13, 2031.
Merck is working on developing new formulations and technologies to maintain its market share after the patent expires.
___
Cytodyn Feb. 24, 2025:
Based on these survival observations, the Company has initiated two pre-clinical studies in mTNBC that will evaluate possible treatment synergies between leronlimab, an antibody-drug complex treatment (sacituzumab govitecan), and an immune checkpoint inhibitor (pembrolizumab).
___
So Merck is the obvious LL/ICI combo for pediatric solid tumors. Which solids are 40% of
(4)
(0)
